TABLE 1.

Baseline characteristics of patients with dilated cardiomyopathy (n = 21).

Baseline characteristics	Cell type		P-value
	Allogeneic (n = 10)	Autologous (n = 11)
Age at injection (years)	58.3 (7.82)	55.909 (10.65)	0.99
Gender
Male	7 (70%)	6 (54.5%)	0.5
Female	3 (30%)	5 (45.5%)	0.5
Ethnicity: Hispanic or Latino	1 (10%)	6 (54.5%)	0.03∗
Race: White	8 (80%)	5 (45.5%)	0.1
Race: Black	1 (10%)	0 (0%)	0.3
History of hypertension	4 (40%)	2 (18.2%)	0.3
New York heart association class
Class I – No limitation	2 (20%)	4 (36.4%)	0.4
Class II – Slight limitation of physical activity	5 (50%)	6 (54.5%)	0.8
Class III – Marked limitation of physical activity	3 (30%)	1 (9.1%)	0.2
History of congestive heart failure	5 (50%)	5 (45.5%)	0.8
History of Valvular heart disease	1 (10%)	0 (0%)	0.3
History of smoking	7 (70%)	4 (36.4%)	0.3
History of diabetes	0 (0%)	1 (9.1%)	0.3
Peak VO2 (mL/kg/min)	17.23 ± 6.8	15.91 ± 5.94	0.6
Six minute walk test (meters)	437.78 m ± 66.95	425.27 m ± 74.66	0.7
Forced expiratory volume in one second (%)	2.43% (0.51)	2.41% (0.9)	0.9
MLHF: Median (IQR)	44.6 (24.75–68)	39 (21–67)	0.6
LV size and function
Ejection fraction (%)	24.4% ± 5.52	21% ± 7.68	0.3
Left ventricular end diastolic volume (mL): Median (IQR)	253.8 mL (225.2–272.45)	193.2 mL (172.55–330.9)	0.7
Left ventricular systolic volume (mL): Median (IQR)	196.15 mL (171.73–219.95)	164 mL (125.5–290.8)	0.7
End diastolic diameter (cm): Median (IQR)	7 cm (6.63–7.18)	6.1 cm (5.85–7.65)	0.9
Biomarkers
EPC-CFUs	3 ± 2 colonies	5 ± 3 colonies	0.08
TNFα	24.5 ± 5.6 pg/mL	25.3 ± 13.3 pg/mL	0.9

Patient data are broken down by cell treatment, allogeneic (n = 10) vs. autologous (n = 11). Values are presented as n, n (%), or mean ± standard deviation. T-Tests and Chi-squared tests were used to compare groups, and statistically significant differences are indicated by bolding and an asterisk.